Advertisement

Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy

Published:December 23, 2016DOI:https://doi.org/10.1016/j.urology.2016.12.027

      Objective

      To evaluate whether baseline prostate atrophy (PA) extent is associated with prostate cancer (PCa) incidence at 2-year repeat prostate biopsy in a clinical trial with systematic biopsies.

      Materials and Methods

      We performed a retrospective analysis of 3165 men 50-75 years old with prostate-specific antigen between 2.5 and 10 ng/mL and a prior negative biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events trial who underwent a 2-year repeat biopsy. PA extent was defined as the percentage of cores with atrophic changes. The association of baseline PA with positive 2-year biopsies was evaluated with logistic regression in uni- and multivariable analysis, controlling for baseline covariates.

      Results

      PA involving none, 1%-25%, 26%-50%, 51%-75%, and >75% of the baseline cores was observed in 966 of 3165 (30.5%), 1189 of 3165 (37.6%), 677 of 3165 (21.4%), 209 of 3165(6.6%), and 124 of 3165 (3.9%) cases, respectively. More extensive PA was associated with older age, lower prostate-specific antigen, larger prostate volume, and higher prevalence of acute and chronic inflammations (all P < .05). Compared to subjects without PA, those with 1%-25%, 26%-50%, 51%-75%, and >75% core involvement had an odds ratio for PCa of 0.65 (95% confidence interval [CI] = 0.52-0.81), 0.60 (95% CI = 0.46-0.78), 0.56 (95% CI = 0.37-0.86), and 0.35 (95% CI = 0.19-0.67), respectively. In multivariable analysis, the extent of PA was independently associated with lower PCa risk (P < .001). More extensive PA was associated with lower incidence of low-grade (Gleason 2-6) and high-grade (Gleason 7-10) PCa.

      Conclusion

      The extent of baseline PA is independently associated with lower PCa risk in a dose-dependent fashion.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Postma R.
        • Schroder F.H.
        • van der Kwast T.H.
        Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
        Urology. 2005; 65: 745-749
        • Davidsson S.
        • Fiorentino M.
        • Andrén O.
        • et al.
        Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.
        Cancer Epidemiol Biomarkers Prev. 2011; 20: 2280-2287
        • Billis A.
        Prostatic atrophy: an autopsy study of a histologic mimic of adenocarcinoma.
        Mod Pathol. 1998; 11: 47-54
        • Prando A.
        • Billis A.
        Focal prostatic atrophy: mimicry of prostatic cancer on TRUS and 3D-MRSI studies.
        Abdom Imaging. 2009; 34: 271-275
        • Wang W.
        • Bergh A.
        • Damber J.E.
        Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate.
        Prostate. 2009; 69: 1378-1386
        • Brasil A.A.
        • Favaro W.J.
        • Cagnon V.H.
        • et al.
        Atrophy in specimens of radical prostatectomy: is there topographic relation to high-grade prostatic intraepithelial neoplasia or cancer?.
        Int Urol Nephrol. 2011; 43: 397-403
        • Billis A.
        • Freitas L.L.
        • Magna L.A.
        • et al.
        Inflammatory atrophy on prostate needle biopsies: is there topographic relationship to cancer?.
        Int Braz J Urol. 2007; 33 (discussion 361-3): 355-360
        • Servian P.
        • Celma A.
        • Planas J.
        • et al.
        Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies.
        Prostate. 2015; 75: 1669-1675
        • Moreira D.M.
        • Bostwick D.G.
        • Andriole G.L.
        • et al.
        Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy.
        J Urol. 2015; 194: 1241-1246
        • Hill A.B.
        The environment and disease: association or causation?.
        Proc R Soc Med. 1965; 58: 295-300
        • Andriole G.L.
        • Bostwick D.G.
        • Brawley O.W.
        • et al.
        Effect of dutasteride on the risk of prostate cancer.
        New Engl J Med. 2010; 362: 1192-1202
        • Iczkowski K.A.
        • Qiu J.
        • Qian J.
        • et al.
        The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
        Urology. 2005; 65: 76-82
        • De Marzo A.M.
        • Nakai Y.
        • Nelson W.G.
        Inflammation, atrophy, and prostate carcinogenesis.
        Urol Oncol. 2007; 25: 398-400
        • Tomas D.
        • Kruslin B.
        • Rogatsch H.
        • et al.
        Different types of atrophy in the prostate with and without adenocarcinoma.
        Eur Urol. 2007; 51: 98-103
        • Davidsson S.
        • Fiorentino M.
        • Andren O.
        • et al.
        Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.
        Cancer Epidemiol Biomarkers Prev. 2011; 20: 2280-2287
        • Muller R.L.
        • Gerber L.
        • Moreira D.M.
        Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial.
        Eur Urol. 2012; 62: 757-764
        • Boehm K.
        • Valdivieso R.
        • Meskawi M.
        • et al.
        BPH: a tell-tale sign of prostate cancer? Results from the prostate cancer and environment study (PROtEuS).
        World J Urol. 2015; 33: 2063-2069
        • Billis A.
        • Meirelles L.R.
        • Magna L.A.
        • et al.
        Extent of prostatic atrophy in needle biopsies and serum PSA levels: is there an association?.
        Urology. 2007; 69: 927-930